-- Supplementary Material -

Impairments in goal-directed action and reversal learning in a proportion of individuals with psychosis: evidence for differential phenotypes in early and persistent psychosis

Short title: Psychosis subgroup with select decision-making deficits

Shuichi Suetani^{1,2,3,4}, Andrea Baker¹, Kelly Garner², Peter Cosgrove¹, Matilda Mackay-Sim⁵, Dan Siskind³, Graham K Murray^{6,7,8}, James G Scott^{1,5,9} and James P Kesby^{2,9*}

- ¹ Queensland Centre for Mental Health Research, Wacol, QLD 4076, Australia.
- ² Queensland Brain Institute, The University of Queensland, St Lucia, QLD 4072, Australia.
- ³ Metro South Addiction and Mental Health Services, Woolloongabba, QLD 4102, Australia.
- ⁴School of Medicine, Griffith University, Nathan, QLD 4111, Australia.
- ⁵ Metro North Mental Health, Royal Brisbane and Women's Hospital, Herston, QLD 4029, Australia.
- ⁶ Department of Psychiatry, University of Cambridge, Cambridge, UK.
- ⁷ Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK.
- ⁸ Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
- ⁹ QIMR Berghofer Medical Research Institute, Herston, QLD 4029, Australia.

* Corresponding author:

Dr. James Kesby

Queensland Brain Institute, The University of Queensland, Brisbane, QLD 4072, Australia.

Phone: +61 7 3346 6363 Fax: +61 7 3346 6301 Email: j.kesby@uq.edu.au

ORCID: 0000-0002-5814-8062

SUPPLEMENTARY METHODS

Procedures and experimental design

We recruited people with psychosis from Metro North Hospital and Health Services, and Metro South Addiction and Mental Health Services in Brisbane, Australia. Healthy controls were recruited from using brochures advertising the study. Participants were informed that they would receive \$30 AUD for taking part in testing but could win a further \$10 AUD based in the credits earned in the behavioural tasks. To avoid reduced compensation for those with psychosis and cognitive impairments, all participants were informed they had passed the 'threshold' required for the full \$10 compensation. Testing order was as follows: Substance Misuse Scale, outcome devaluation instrumental training, TOPF, devaluation testing, WASI-II, reversal learning training stage, and reversal learning test stage.

Inclusion criteria

Those with early psychosis were recruited from Early Psychosis Clinics. Those with persistent psychosis must have been diagnosed with a Persistent Psychotic Disorder (schizophrenia, schizoaffective disorder, Bipolar I Disorder, Delusional Disorder). Participants had no organic cause pf psychosis (i.e., epilepsy, intra-cranial pathology or HIV infection), and were between

the ages of 18 and 50. Subjects were classified as early psychosis if they had received less than 6 months of antipsychotic therapy.

Serial reversal learning task

For all stages of the reversal learning task, there were no limits on the time taken to respond. After selecting a stimulus, the outcome was presented on the screen for one second before the next trial was initiated. A running total of the 'credits' received was displayed in the bottom corner of the screen (participants were not aware of how much each credit was worth in monetary compensation). All stimulus pairs were binary images matched as closely as possible for white-black pixel ratio (see *Fig S2*), with all combinations counterbalanced.

Initial training

Participants were shown the following instructions on the screen: "Two pictures will appear on the screen. On each turn, use the joystick to choose one of these pictures. The computer will tell you what credits you earned for your choice. One of the pictures will get you a reward and the other will not. The pictures will change sides randomly, so be careful to select the correct one". They then began a deterministic discrimination with a single reversal, whereby every correct response was rewarded (outcome of 1) and incorrect responses were not (outcome of 0). The initial discrimination contingencies were reversed after 8 consecutive correct responses were made and both stages had to be completed within 200 trials (participants got up to two attempts using unique sets of stimuli).

Probabilistic SRL

After successfully completing the training stage, participants were administered a probabilistic SRL task. Two instruction screens were presented, with the first restating the instruction from the training test. The second informed the participants of the probabilistic contingencies: "Unlike before, the correct picture will not always give you a reward and sometimes the wrong picture will give you a reward. Find out which picture earns the most credits. Stick with it even if it is sometimes wrong. At some point it may change so that the other picture earns more. Only start choosing the other picture when you are sure that the rule has changed".

The task consisted of 11 stages, each featuring the same pair of stimuli but varying in reward rate (probabilistic) and reward value (credits awarded). These included: initial discrimination (1 stage), initial reversal (1 stage), and serial reversal learning phase 1 (SRL1; 5 stages) and serial reversal learning phase 2 (SRL2; 4 stages). For the discrimination, initial reversal and SRL1 stages, the probabilistic reward contingencies were set at 80/20, meaning that the target stimulus was rewarded 80% of the time, whereas the non-target stimulus was rewarded only 20% of the time. The reward outcomes included 1 credit for a rewarded trial and 0 credits for a non-rewarded trial. For the SRL2 stages, the probabilistic reward contingencies were set at 80/40 to increase the task difficulty, meaning that the target stimulus was rewarded 80% of the time, whereas the non-target stimulus was rewarded 40% of the time. The reward outcomes were 2 or 6 credits for a rewarded trial (of equal probability) and 0 credits for a non-rewarded trial. The addition of variable reward values was included to analyze whether the strategy a participant used was biased when receiving greater rewards on the preceding trial. Criterion for progressing to the next stage was 6 correct responses in a row. The test ended once the participant completed all 11 stages, or once 500 trials were completed. SRL1 and SRL2 trials to criterion were only included in

analyses if at least 2 stages had been completed. All trials (completion of stage or not) were included in all other analyses.

Reversal learning performance measures and strategies

There are multiple measures of performance that can be quantified in reversal learning tasks. These include, but are not limited to, total trials to criterion, perseveration (number of errors in the first 6 trials after a reversal), and response rates (total, or for correct and incorrect responses). Other measures allow for detailed inspections of choice strategy, including whether a subject selects the same stimulus after attaining a reward (Win-stay) or whether they select the other stimulus (Win-shift). Similar strategies were calculated after losses, including whether the subject selects the same stimulus after a non-rewarded trial (Lose-stay) or selects the other stimulus (Lose-shift). These were calculated as the proportion of each strategy relative to the trials in which that strategy could be used (i.e., P.Win-stay = Total number of times the same stimulus was selected after a rewarded trial/total rewarded trials). All values were calculated for each individual stage, as well as across the SRL1 and SRL2 stages (inclusive of all combined trials).

Serial reversal learning exclusions

One participant (a male in the persistent psychosis group) failed to successfully complete the training stages after two attempts. Data from this participant was included in the outcome devaluation data but not for reversal learning or intact/impaired analyses.

SUPPLEMENTARY TABLES

Table S1. Psychiatric characteristics and symptom assessments in those with psychosis.

Grou	S1. Psychiatric characteristics and b	Early	Persistent	$\frac{F/\chi^2}{}$	p	
0.00	r	psychosis	psychosis	- · · · · ·	P	
		(N = 15)	(N = 45)			
Diagr	nosis (% Naff, Aff, Other)	7%*, 20%,	51%, 42%, 7%	28.5	<0.001	***
	cations	, ,	, ,			
Dose	(chlorpromazine equivalent)	211.1 (171.2)	481.0 (411.6)	6.04	0.017	*
Numl	per	1.60 (0.91)	4.07 (2.85)	10.78	0.002	**
Anxie	ty (% Yes)	0.0%	15.6%	2.64	0.104	
Mood	l stabilisers (% Yes)	26.7%	22.2%	0.12	0.724	
Antid	epressants (% Yes)	26.7%	36.6%	0.40	0.527	
Subst	ance dependence (% Yes)	0.0%	11.1%	1.82	0.178	
PANS	SS					
P1	Delusions	2.47 (1.36)	2.22 (1.61)	0.28	0.599	
P2	Conceptual disorganisation	1.47 (0.99)	1.58 (1.22)	0.10	0.750	
Р3	Hallucinatory Behaviour	1.87 (1.25)	2.51 (1.60)	2.01	0.162	
P4	Excitement	1.07 (0.26)	1.40 (0.86)	2.15	0.148	
P5	Grandiosity	2.00 (1.36)	2.11 (1.35)	0.08	0.784	
P6	Suspiciousness/persecution	2.33 (1.50)	2.47 (1.49)	0.09	0.765	
P7	Hostility	1.13 (0.35)	1.22 (0.60)	0.29	0.589	
Posit	ive Scale Total	12.33 (4.67)	13.51 (5.69)	0.52	0.472	
N1	Blunted affect	3.40 (1.40)	2.87 (1.55)	1.40	0.242	
N2	Emotional withdrawal	1.93 (1.10)	1.93 (1.25)	0.00	1.000	
N3	Poor rapport	1.27 (0.70)	1.69 (1.10)	1.92	0.171	
N4	Passive social withdrawal	1.53 (0.83)	1.84 (1.15)	0.93	0.338	
N5	Difficulty in abstract thinking	2.87 (1.06)	3.51 (1.16)	3.61	0.062	
N6	Lack of spontaneity/flow	1.53 (0.99)	1.80 (1.25)	0.56	0.457	
N7	Stereotyped Thinking	1.73 (0.88)	1.89 (1.17)	0.22	0.640	
Nega	tive Scale Total	14.27 (4.30)	15.53 (6.07)	0.56	0.459	
G1	Somatic concern	2.20 (0.77)	2.38 (1.13)	0.32	0.575	
G2	Anxiety	3.33 (1.18)	2.64 (1.42)	2.88	0.095	
G3	Guilt Feelings	2.13 (1.46)	1.69 (1.20)	1.38	0.245	
G4	Tension	2.47 (0.92)	2.02 (0.94)	2.54	0.116	
G5	Mannerisms and posturing	1.47 (0.92)	1.58 (0.99)	0.15	0.703	
G6	Depression	2.87 (0.92)	2.42 (1.45)	1.23	0.272	
G7	Motor retardation	1.53 (0.99)	1.56 (1.12)	0.01	0.946	
G8	Uncooperativeness	1.00 (0.00)	1.18 (0.58)	1.42	0.239	
G9	Unusual thought content	1.60 (0.83)	1.69 (1.00)	0.10	0.757	
G10	Disorientation	2.07 (0.96)	2.33 (0.80)	1.13	0.291	
G11	Poor attention	1.60 (1.06)	1.60 (1.10)	0.00	1.000	
G12	Lack of judgment and insight	3.73 (1.58)	3.09 (1.59)	1.85	0.179	
G13	Disturbance of volition	1.40 (0.83)	1.36 (0.74)	0.04	0.846	
G14	Poor impulse control	1.00 (0.00)	1.18 (0.58)	1.42	0.239	
G15	Preoccupation	1.80 (1.42)	1.84 (1.33)	0.01	0.913	
G16	Active social avoidance	1.80 (1.32)	2.04 (1.30)	0.40	0.531	
	ral Psychopathology Scale	32.00 (8.27)	30.60 (7.39)	0.38	0.540	
	SS Total	58.60 (15.27)	59.64 (15.73)	0.05	0.823	
	ation classifications: Anxioty (Prog					

Medication classifications: Anxiety (Pregabalin, benzodiazepines), Mood stabilisers (lithium), antidepressants (selective serotonin reuptake inhibitors [SSRIs], monoamine oxidase inhibitors, Mirtazapine), and Substance dependence (Naltrexone, buprenorphine, Varenicline). *NAff*, nonaffective disorder; *Aff*, affective disorder; *AP*, antipsychotic. The data are expressed as mean (standard deviation) where applicable. *p<0.05, **p<0.01, ***p<0.001

Table S2. Demographics, IQ and substance use characteristics for control subjects aged matched to those with early psychosis.

Group		Controls (N = 15)	Early psychosis (N = 15)	F/χ²	p	
Demographics						
Age (years)		23.60 (3.29)	21.60 (1.99)	4.05	0.054	
Education (years))	14.73 (2.58)	12.87 (0.92)	6.99	0.013	*
Gender (% male)		46.6%	60.0%	0.54	0.464	
Ethnicity (% Cauc	asian)	86.7%	86.7%	0.00	1.000	
IQ test scores						
TOPF (ss)		115.5 (7.5)	115.5 (8.2)	0.00	0.982	
WASI-II (FISQ-2)		110.8 (9.6)	105.4 (12.3)	1.80	0.190	
Substance use						
Alcohol	Lifetime	93.3%	86.7%	0.37	0.543	
	28d freq	2.00 (1.07)	1.40 (1.12)	2.25	0.145	
Cannabinoids	Lifetime	46.7%	66.7%	1.22	0.269	
	28d freq	0.20 (0.41)	0.80 (1.15)	3.64	0.067	
Nicotine	Lifetime	33.3%	73.3%	4.82	0.028	*
	28d freq	0.07 (0.26)	2.47 (2.80)	10.93	0.003	
Caffeine	Lifetime	86.7%	93.3%	0.37	0.543	
	28d freq	3.93 (2.19)	4.00 (2.10)	0.01	0.933	
Amphetamines	Lifetime	0.0%	33.3%	6.00	0.014	*
	28d freq	0.00 (0.00)	0.00 (0.00)	-	-	
Ecstasy	Lifetime	33.3%	46.7%	0.56	0.456	
	28d freq	0.07 (0.26)	0.00 (0.00)	1.00	0.326	
Opiates	Lifetime	0.0%	6.7%	1.03	0.309	
	28d freq	0.00 (0.00)	0.00 (0.00)	-	-	
Benzodiazepine	Lifetime	6.7%	20.0%	1.15	0.283	
	28d freq	0.00 (0.00)	0.00 (0.00)	-	-	
Other	Lifetime	26.7%	40.0%	0.60	0.439	
	28d freq	0.00 (0.00)	0.00 (0.00)	-	-	
Volatile	Lifetime	0.0%	6.7%	1.03	0.309	
	28d freq	0.00 (0.00)	0.00 (0.00)	-	-	

The data are expressed as mean (standard deviation) where applicable. TOPF, test of premorbid functioning; ss, standard score; WASI-II, Wechsler Abbreviated Scale of Intelligence – 2^{nd} edition; FSIQ-2, Full-Scale IQ. *p<0.05.

Table S3. Outcome-specific devaluation in control subjects aged matched to those with early psychosis.

Group	Controls	Early psychosis	F/χ ²	р
	(N = 15)	(N = 15)		
Instrumental training				
Total trials to criterion	6.93 (1.91)	6.13 (0.52)	2.46	0.128
Total correct trials	6.47 (1.36)	6.07 (0.26)	1.26	0.271
Response rate (s)	1.45 (0.69)	1.38 (0.71)	0.06	0.807
Correct response rate (s)	1.27 (0.67)	1.35 (0.70)	0.11	0.741
Devaluation rating change	es			
Valued stimulus	0.80 (1.21) aaa	0.20 (1.08) aa	2.05	0.163
Devalued stimulus	-1.47 (1.36)	-1.87 (1.81)	0.47	0.499
Irrelevant stimulus	0.33 (0.90)	0.07 (1.03)	0.57	0.457
Motivation to earn credits	0.13 (0.92)	0.13 (0.92)	0.00	1.000
Outcome-specific devalua	tion			
Valued response ratio	0.76 (0.41) ^a	0.87 (0.28) aaa	0.70	0.410
Devalued response ratio	0.24 (0.41)	0.13 (0.28)	0.70	0.410
Valued response rate (/s)	2.55 (1.60)	2.60 (1.52) aa	0.01	0.944
Devalued response rate	1.04 (1.80)	0.47 (1.11)	1.07	0.309
Probe questions				
Average correct responses	1.33 (0.90)	1.73 (0.59)	2.07	0.162

The data are expressed as mean (standard deviation) where applicable. ${}^{a}p<0.05$, ${}^{aa}p<0.01$, ${}^{aaa}p<0.001$ valued outcome compared with equivalent devalued outcome (paired t-test within group).

Table S4. Serial reversal learning in control subjects aged matched to those with early psychosis.

Group	Controls	Early psychosis	F/χ²	р	
•	(N = 15) †	(N = 15)	,,,	•	
Trials to criterion					
Initial discrimination	27.33 (69.74)	17.07 (9.80)	.032	0.577	
First reversal	12.33 (6.18)	17.40 (14.24)	1.60	0.217	
SRL1	13.69 (10.77)	16.56 (16.52)	0.32	0.578	
SRL2	18.84 (10.60)	21.12 (17.81)	0.17	0.681	
Strategy use					
SRL1 Win-stay	0.96 (0.11)	0.93 (0.14)	0.60	0.447	
SRL1 Lose-shift	0.51 (0.29)	0.48 (0.20)	0.10	0.760	
SRL2 Win-stay	0.93 (0.10)	0.86 (0.19)	1.30	0.264	
SRL2 Win-stay 2	0.89 (0.15)	0.85 (0.18)	0.40	0.535	
SRL2 Win-stay 6	0.96 (0.06)	0.87 (0.20)	2.70	0.112	
SRL2 Lose-shift	0.53 (0.28)	0.35 (0.14)	4.79	0.037	*
Computational modelling					
EWA <i>phi</i>	0.28 (0.22)	0.24 (0.15)	0.49	0.491	
EWA rho	0.22 (0.22)	0.27 (0.29)	0.25	0.622	
EWA <i>beta</i>	2.53 (0.67)	2.06 (0.76)	3.25	0.082	
RP rew	0.870 (0.017)	0.864 (0.017)	0.87	0.360	
RP <i>pun</i>	0.66 (0.22)	0.71 (0.16)	0.55	0.464	
RP beta	3.07 (1.17)	2.13 (1.47)	3.76	0.063	

The data are expressed as mean (standard deviation) where applicable. † for SRL2 outcomes, N = 14. *p<0.05.

Table S5. Demographics, IQ and substance use characteristics in persistent psychosis.

Group		Controls	Persistent	F/ χ ²	p	
			psychosis			
		(N = 34)	(N = 45)			
Demographic cha	racteristics					
Age (years)		32.4 (9.9)	31.0 (8.8)	0.39	0.536	
Education (years)		14.9 (2.7)	11.5 (2.0)	40.53	<0.001	**
Gender (% male)		44.1%	73.3%	6.93	0.008	**
Ethnicity (% Cauca	sian)	85.29%	66.7%	3.55	0.059	
IQ test scores						
TOPF (ss)		112.2 (8.9)	98.0 (14.4)	25.43	<0.001	**
WASI-II (FISQ-2)		110.1 (10.0)	89.5 (16.9)	40.33	<0.001	**
Substance use						
Alcohol	Lifetime	97.1%	91.1%	1.16	0.282	
	28d freq	2.26 (1.33)	1.00 (1.26)	18.55	< 0.001	**
Cannabinoids	Lifetime	61.8%	82.2%	4.15	0.042	*
	28d freq	0.32 (1.01)	0.53 (1.27)	0.63	0.431	
Nicotine	Lifetime	50.0%	84.4%	10.86	< 0.001	**
	28d freq	0.85 (2.02)	3.87 (2.84)	27.67	< 0.001	**
Caffeine	Lifetime	82.4%	95.6%	3.71	0.054	
	28d freq	4.00 (2.23)	4.18 (2.20)	0.13	0.724	
Amphetamines	Lifetime	8.8%	53.3%	17.06	< 0.001	**
•	28d freq	0.00 (0.00)	0.09 (0.47)	1.22	0.272	
Ecstasy	Lifetime	23.5%	55.6%	8.17	0.004	**
•	28d freq	0.03 (0.17)	0.04 (0.30)	0.69	0.793	
Opiates	Lifetime	2.9%	17.8%	4.22	0.040	*
'	28d freq	0.00 (0.00)	0.00 (0.00)	-	_	
Benzodiazepines	Lifetime	5.9%	24.4%	4.85	0.028	*
1-	28d freq	0.00 (0.00)	0.00 (0.00)	-	-	
Other	Lifetime	26.5%	35.6%	0.74	0.390	
-	28d freq	0.06 (0.34)	0.00 (0.00)	0.88	0.418	
Volatile	Lifetime	2.9%	17.8%	4.22	0.040	*
	28d freq	0.00 (0.00)	0.00 (0.00)	_	_	

The data are expressed as mean (standard deviation) where applicable. TOPF, test of premorbid functioning; ss, standard score; WASI-II, Wechsler Abbreviated Scale of Intelligence – 2^{nd} edition; FSIQ-2, Full-Scale IQ. *p<0.05, **p<0.01, ***p<0.001.

Table S6. Outcome-specific devaluation in control subjects those with persistent psychosis.

Group	Controls	Persistent psychosis	F/χ²	р	
	(N = 34)	(N = 44)			
Instrumental training					
Total trials to criterion	6.82 (2.38)	7.39 (2.75)	0.90	0.345	
Total correct trials	6.44 (1.62)	6.59 (1.65)	0.16	0.689	
Response rate (s)	1.45 (0.63)	2.05 (1.37)	5.56	0.021	*
Correct response rate (s)	1.34 (0.63)	1.73 (1.17)	3.09	0.083	
Devaluation rating change	es				
Valued stimulus	1.03 (1.45) aaa	0.93 (1.39) aaa	0.09	0.763	
Devalued stimulus	-2.06 (2.03)	-1.07 (2.18)	4.20	0.044	*
Irrelevant stimulus	0.00 (1.30)	-0.07 (1.81)	0.03	0.853	
Motivation to earn credits	0.00 (0.98)	-0.14 (1.19)	0.29	0.591	
Outcome-specific devalua	tion				
Valued response ratio	0.85 (0.33) aaa	0.67 (0.29) aaa	6.86	0.011	*
Devalued response ratio	0.15 (0.33)	0.33 (0.29)	6.86	0.011	*
Valued response rate (/s)	2.86 (1.42) aaa	1.83 (1.12) aaa	12.75	< 0.001	**
Devalued response rate	0.59 (1.37)	0.77 (0.73)	0.52	0.472	
Probe questions					
Average correct responses	1.44 (0.79)	1.27 (0.85)	0.81	0.371	

The data are expressed as mean (standard deviation) where applicable. *p<0.05, ***p<0.001. *aaap<0.001 valued outcome compared with equivalent devalued outcome (paired t-test within group).

Table S7. Serial reversal learning in control subjects those with persistent psychosis.

Group	Controls	Persistent psychosis	F/χ²	p	
	(N = 34) †	(N = 44) †			
Trials to criterion					
Initial discrimination	19.85 (46.53)	18.18 (14.09)	0.05	0.822	
First reversal	12.71 (6.95)	25.45 (35.11)	4.34	0.041	*
SRL1	14.06 (9.65)	20.87 (18.59)	3.76	0.056	
SRL2	22.64 (19.11)	30.45 (27.35)	1.86	0.177	
Strategy use					
SRL1 Win-stay	0.97 (0.08)	0.88 (0.15)	9.00	0.004	**
SRL1 Lose-shift	0.55 (0.26)	0.59 (0.20)	0.80	0.374	
SRL2 Win-stay	0.90 (0.14)	0.82 (0.16)	5.39	0.023	*
SRL2 Win-stay 2	0.88 (0.16)	0.81 (0.18)	3.49	0.066	
SRL2 Win-stay 6	0.92 (0.16)	0.82 (0.17)	6.22	0.015	*
SRL2 Lose-shift	0.52 (0.25)	0.57 (0.25)	0.96	0.330	
Computational modelling					
EWA <i>phi</i>	0.22 (0.19)	0.12 (0.13)	7.19	0.009	**
EWA rho	0.22 (0.19)	0.34 (0.27)	4.57	0.036	*
EWA <i>beta</i>	2.53 (0.78)	2.02 (0.73)	8.56	0.005	**
RP rew	0.87 (0.02)	0.86 (0.03)	4.74	0.033	*
RP <i>pun</i>	0.72 (0.23)	0.84 (0.21)	4.96	0.029	*
RP <i>beta</i>	2.90 (1.35)	1.80 (1.34)	12.75	< 0.001	**

The data are expressed as mean (standard deviation) where applicable. † for SRL2 outcomes, N = 33 for control and N = 41 for persistent psychosis groups. *p<0.05, **p<0.01, ***p<0.001.

Table S8. Demographics, IQ and substance use characteristics for control subjects split for intact or impaired goal-directed action.

Group		Control	Control
Goal-directed action		intact	impaired
		(N = 28)	(N = 6)
Demographics			
Age (years)		32.3 (10.0)	32.5 (10.4)
Education (years))	14.7 (2.8)	15.5 (2.0)
Gender (% male)		35.7%	83.3%
Ethnicity (% Cauc	asian)	89.3%	66.7%
IQ test scores			
TOPF (ss)		111.5 (9.4)	115.2 (6.4)
WASI-II (FISQ-2)		110.1 (10.7)	110.3 (5.9)
Substance use			
Alcohol	Lifetime	100.0%	83.3%
	28d freq	2.25 (1.29)	2.33 (1.63)
Cannabinoids	Lifetime	64.3%	50.0%
	28d freq	0.21 (0.63)	0.83 (2.04)
Nicotine	Lifetime	50.0%	50.0%
	28d freq	0.82 (1.96)	1.00 (2.45)
Caffeine	Lifetime	82.1%	83.3%
	28d freq	3.93 (2.26)	4.33 (2.25)
Amphetamines	Lifetime	7.1%	16.7%
	28d freq	_	_
Ecstasy	Lifetime	21.4%	33.3%
	28d freq	0.04 (0.19)	_
Opiates	Lifetime	3.6%	0.0%
	28d freq	_	_
Benzodiazepine	Lifetime	7.1%	0.0%
	28d freq	_	_
Other	Lifetime	25.0%	33.3%
	28d freq	0.07 (0.38)	_
Volatile	Lifetime	0.0%	16.7%
	28d freq	_	_

The data are expressed as mean (standard deviation) where applicable. TOPF, test of premorbid functioning; ss, standard score; WASI-II, Wechsler Abbreviated Scale of Intelligence – 2nd edition; FSIQ-2, Full-Scale IQ.

Table S9. Demographics, IQ and substance use characteristics for those with early psychosis split for intact or impaired goal-directed action.

Group		Early psychosis	Early psychosis
Goal-directed action		intact (N = 12)	impaired (N = 3)
Demographics			
Age (years)		21.5 (2.2)	22.0 (1.0)
Education (years))	12.8 (1.0)	13.3 (0.6)
Gender (% male)		50.0%	100.0%
Ethnicity (% Cauc	asian)	83.3%	100.0%
IQ test scores			
TOPF (ss)		117.4 (8.0)	108.0 (2.0)
WASI-II (FISQ-2)		107.9 (11.0)	95.3 (14.0)
Substance use			
Alcohol	Lifetime	83.3%	100.0%
	28d freq	1.17 (1.03)	2.33 (1.15)
Cannabinoids	Lifetime	58.3%	100.0%
	28d freq	0.92 (1.24)	0.33 (0.58)
Nicotine	Lifetime	66.7%	100.0%
	28d freq	2.75 (2.93)	1.33 (2.31)
Caffeine	Lifetime	91.7%	100.0%
	28d freq	3.83 (2.25)	4.67 (1.53)
Amphetamines	Lifetime	33.3%	33.3%
	28d freq	_	_
Ecstasy	Lifetime	50.0%	33.3%
	28d freq	_	_
Opiates	Lifetime	0.0%	33.3%
	28d freq	_	_
Benzodiazepine	Lifetime	16.7%	33.3%
	28d freq	_	_
Other	Lifetime	41.7%	33.3%
	28d freq	_	_
Volatile	Lifetime	8.3%	0.0%
	28d freq	_	

The data are expressed as mean (standard deviation) where applicable. TOPF, test of premorbid functioning; ss, standard score; WASI-II, Wechsler Abbreviated Scale of Intelligence – 2nd edition; FSIQ-2, Full-Scale IQ.

Table S10. Psychiatric characteristics and symptom assessments for those with early psychosis split for intact or impaired goal-directed action.

Group	Early psychosis	Early psychosis
Goal-directed action	intact (N = 12)	impaired (N = 3)
Medications		
Dose (CPZ equivalent)	202.7 (178.2)	245.0 (168.5)
Number	1.67 (0.98)	1.33 (0.58)
Anxiety (% Yes)	0.0%	0.0%
Mood stabilisers (% Yes)	25.0%	33.3%
Antidepressants (% Yes)	33.3%	0.0%
Dependence (% Yes)	0.0%	0.0%
PANSS		
Positive Scale Total	11.92 (5.16)	14.00 (1.00)
Negative Scale Total	14.42 (4.40)	13.67 (4.73)
Psychopathology Total	33.00 (8.84)	28.00 (4.36)
PANSS Total	59.33 (16.74)	55.67 (8.74)

Medication classifications: Anxiety (Pregabalin, benzodiazepines), Mood stabilisers (lithium), antidepressants (selective serotonin reuptake inhibitors [SSRIs], monoamine oxidase inhibitors, Mirtazapine), and Substance dependence (Naltrexone, buprenorphine, Varenicline). CPZ, chlorpromazine. The data are expressed as mean (standard deviation) where applicable.

Table S11. Demographics, IQ and substance use characteristics for those with persistent psychosis split for intact or impaired goal-directed action.

Group		Control	Persistent psychosis	Persistent psychosis	F/ χ²	p
Goal-directed action		intact	intact	impaired		
		(N = 28)	(N = 18)	(N = 25)		
Demographic cha	racteristics					
Age (years)		32.3 (10.0)	31.6 (9.6)	31.2 (8.4)	0.10	0.902
Education (years)		14.7 (2.8)	12.4 (1.5) ##	10.9 (2.1) ###	18.75	<0.001
Gender (% male)		35.7%	77.8%	68.0%	9.61	0.008
Ethnicity (% Cauca	sian)	89.3%	83.3%	56.0%	8.74	0.013
IQ test scores						
TOPF (ss)		111.5 (9.4)	103.8 (9.8)	94.5 (15.1) ###	13.81	< 0.001
WASI-II (FISQ-2)		110.1 (10.7)	98.8 (14.9) #	83.5 (14.5) **	26.62	<0.001
Substance use						
Alcohol	Lifetime	100.0%	88.9%	96.0%	3.35	0.188
	28d freq	2.25 (1.29)	1.33 (1.46)	0.84 (1.11)###	8.33	0.001
Cannabinoids	Lifetime	64.3%	72.2%	88.0%	4.00	0.135
	28d freq	0.21 (0.63)	0.67 (1.57)	0.48 (1.08)	1.00	0.375
Nicotine	Lifetime	50.0%	83.3%	84.0% #	9.26	0.010
	28d freq	0.82 (1.96)	3.33 (2.91)##	4.08 (2.86) ###	11.72	<0.001
Caffeine	Lifetime	82.1%	94.4%	96.0%	3.36	0.187
	28d freq	3.93 (2.26)	4.17 (2.28)	4.04 (2.21)	0.06	0.940
Amphetamines	Lifetime	7.1%	44.4% #	60.0% #	17.08	< 0.001
	28d freq	0.00 (0.00)	0.00 (0.00)	0.16 (0.62)	1.51	0.229
Ecstasy	Lifetime	21.4%	61.1% #	52.0%	8.57	0.014
	28d freq	0.04 (0.19)	0.11 (0.47)	0.00 (0.00)	0.94	0.395
Opiates	Lifetime	3.6%	16.7%	20.0%	3.57	0.168
	28d freq	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	-	-
Benzodiazepines	Lifetime	7.1%	38.9% #	16.0%	7.52	0.023
	28d freq	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	-	-
Other	Lifetime	25.0%	44.4%	28.0%	2.10	0.350
	28d freq	0.07 (0.38)	0.00 (0.00)	0.00 (0.00)	0.76	0.470
Volatile	Lifetime	0.0%	22.2% #	16.0%	6.276	0.043
	28d freq	0.00 (0.00)	0.00 (0.00)	0.00 (0.00)	-	-

The data are expressed as mean (standard deviation) where applicable. TOPF, test of premorbid functioning; ss, standard score; WASI-II, Wechsler Abbreviated Scale of Intelligence – 2^{nd} edition; FSIQ-2, Full-Scale IQ. **p<0.01 compared with all groups; *p<0.05, *p<0.01, *p<0.01 compared with Controls.

Table S12. Psychiatric characteristics and symptom assessments for those with persistent psychosis split for

intact or impaired goal-directed action.

Grou	or impaired goal-directed action. p	Persistent	Persistent	F/χ ²	p	
	•	psychosis	psychosis		•	
Goal-	directed action	intact	impaired			
		(N = 18)	(N = 25)			
	nosis (% Naff, Aff, Other)	56%, 44%, 0%	44%, 39%, 17%	4.51	0.105	
	cations					
	(chlorpromazine equivalent)	424.8 (225.9)	521.8 (513.8)	0.56	0.458	
Numl		3.61 (2.97)	4.48 (2.80)	0.96	0.334	
	ety (% Yes)	11.1%	20.0%	0.61	0.436	
	d stabilisers (% Yes)	27.8%	16.0%	0.88	0.349	
	epressants (% Yes)	33.3%	40.0%	0.20	0.655	
PANS	ance dependence (% Yes)	16.7%	8.0%	0.77	0.382	
P1	Delusions	2.39 (1.72)	2.20 (1.58)	0.14	0.711	
P2	Conceptual disorganisation	1.72 (1.41)	1.52 (1.12)	0.28	0.603	
P3	Hallucinatory Behaviour	2.44 (1.85)	2.60 (1.47)	0.09	0.761	
P4	Excitement	1.61 (1.04)	1.28 (0.74)	1.50	0.227	
P5	Grandiosity	2.72 (1.53)	1.64 (1.08)	7.46	0.009	**
P6	Suspiciousness/persecution	2.39 (1.58)	2.56 (1.50)	0.13	0.720	
P7	Hostility	1.06 (0.24)	1.36 (0.76)	2.71	0.108	
Posit	ive Scale Total	14.33 (6.13)	13.16 (5.59)	0.43	0.518	
N1	Blunted affect	2.56 (1.62)	3.08 (1.44)	1.25	0.270	
N2	Emotional withdrawal	1.67 (1.14)	2.08 (1.29)	1.19	0.283	
N3	Poor rapport	1.39 (1.04)	1.84 (1.07)	1.91	0.174	
N4	Passive social withdrawal	1.89 (1.28)	1.88 (1.09)	0.00	0.981	
N5	Difficulty in abstract thinking	2.94 (1.00)	3.88 (1.01)	9.03	0.005	**
N6	Lack of spontaneity/flow	1.39 (1.14)	2.00 (1.15)	2.95	0.093	
N7	Stereotyped Thinking	1.94 (1.30)	1.72 (1.02)	0.40	0.530	
_	tive Scale Total	13.78 (6.30)	16.48 (5.61)	2.19	0.146	
G1	Somatic concern	2.61 (1.20)	2.24 (1.09)	1.12	0.296	
G2	Anxiety	2.56 (1.42)	2.84 (1.40)	0.42	0.518	
G3	Guilt Feelings	1.83 (1.38)	1.56 (1.08)	0.53	0.471	
G4	Tension	1.89 (0.96)	2.20 (0.91)	1.16	0.288	
G5	Mannerisms and posturing	1.50 (0.86)	1.64 (1.11)	0.20	0.658	
G6	Depression Motor retardation	2.56 (1.54)	2.44 (1.42)	0.07	0.801	
G7 G8	Motor retardation Uncooperativeness	1.33 (1.03) 1.00 (0.00)	1.60 (1.00) 1.24 (0.66)	0.73 2.34	0.399 0.134	
G9	Unusual thought content	1.89 (1.13)	1.60 (0.91)	0.86	0.134	
G10	Disorientation	2.17 (0.86)	2.52 (0.71)	2.17	0.149	
G11	Poor attention	1.39 (1.24)	1.80 (1.00)	1.44	0.143	
G12	Lack of judgment and insight	2.78 (1.59)	3.24 (1.64)	0.85	0.362	
G13	Disturbance of volition	1.50 (0.92)	1.28 (0.61)	0.88	0.353	
G14	Poor impulse control	1.22 (0.65)	1.16 (0.55)	0.12	0.736	
G15	Preoccupation	1.72 (1.36)	1.84 (1.21)	0.09	0.767	
G16	Active social avoidance	1.83 (1.42)	2.20 (1.22)	0.82	0.371	
	ral Psychopathology Scale	29.78 (9.72)	31.40 (5.53)	0.48	0.491	
	SS Total	57.89 (19.70)	61.04 (12.81)	0.40	0.528	
Modic	ation classifications: Anviety (Preg	abalia banzadiaza	nings) Magd stabili	care (lithiu	m) antidonr	accapt

Medication classifications: Anxiety (Pregabalin, benzodiazepines), Mood stabilisers (lithium), antidepressants (selective serotonin reuptake inhibitors [SSRIs], monoamine oxidase inhibitors, Mirtazapine), and Substance dependence (Naltrexone, buprenorphine, Varenicline). NAff, nonaffective disorder; Aff, affective disorder. The data are expressed as mean (standard deviation) where applicable. **p<0.01.

Table S13. Outcome-specific devaluation in controls and those with persistent psychosis split for intact or impaired goal-directed action.

Group	Control	Persistent psychosis	Persistent psychosis	F/χ²	р
Goal-directed action	intact (N = 28)	intact (N = 18)	impaired (N = 25)		
Instrumental training					
Total trials to criterion	6.21 (0.63)	7.00 (2.87)	7.44 (2.50)	2.31	0.107
Total correct trials	6.07 (0.38)	6.33 (1.41)	6.68 (1.77)	1.47	0.237
Response rate (s)	1.48 (0.64)	2.03 (1.15)	1.80 (0.86)	2.38	0.100
Correct response rate (s)	1.38 (0.67)	1.89 (1.20)	1.44 (0.65)	2.27	0.111
Devaluation rating change	es				
Valued stimulus	1.14 (1.51) ^{aaa}	0.72 (1.02) aaa	1.04 (1.62) a	0.48	0.622
Devalued stimulus	-2.21 (1.93)	-2.22 (1.99)	-0.28 (2.01) **	7.80	0.001
Irrelevant stimulus	0.04 (1.43)	-0.28 (2.24)	0.08 (1.50)	0.27	0.766
Motivation to earn credits	0.14 (0.89)	0.28 (0.75)	-0.48 (1.36)	3.43	0.038
Outcome-specific devalua	tion				
Valued response ratio	0.99 (0.03) aaa	0.98 (0.05) aaa	0.45 (0.17) ***	47.05	< 0.001
Devalued response ratio	0.01 (0.03)	0.02 (0.05)	0.55 (0.17) ***	112.91	<0.001
Valued response rate (/s)	3.26 (1.03) aaa	2.88 (0.77) aaa	1.08 (0.66) ***	203.38	< 0.001
Devalued response rate	0.02 (0.06)	0.07 (0.16)	1.27 (0.54) ***	203.38	<0.001
Probe questions					
Average correct responses	1.61 (0.69)	1.56 (0.51)	1.12 (0.97)	3.05	0.054

The data are expressed as mean (standard deviation) where applicable. **p<0.01, ***p<0.001 compared with all groups; *p<0.05, **p<0.05, **p<0.001 valued outcome compared with equivalent devalued outcome (paired t-test within group).

Table S14. Serial reversal learning in controls and those with persistent psychosis split for intact or impaired goal-directed action.

Group	Control	Persistent psychosis	Persistent psychosis	F/χ²	р
Goal-directed action	intact (N = 28) †	intact (N = 18)	impaired (N = 25) †		
Trials to criterion					
Initial discrimination	21.89 (51.16)	17.22 (13.74)	19.12 (14.79)	0.11	0.897
First reversal	12.29 (6.83)	17.78 (11.89)	31.60 (44.89) #	3.34	0.042
SRL1	14.59 (10.48)	13.57 (8.21)	26.51 (22.49) *	5.12	0.009
SRL2	20.08 (13.33)	21.74 (9.96)	38.60 (35.54) #	4.46	0.016
Strategy use					
SRL1 Win-stay	0.96 (0.09)	0.95 (0.09)	0.83 (0.16) **	9.57	<0.001
SRL1 Lose-shift	0.55 (0.26)	0.62 (0.20)	0.59 (0.18)	0.73	0.484
SRL2 Win-stay	0.91 (0.13)	0.84 (0.12)	0.78 (0.19)#	4.07	0.022
SRL2 Win-stay 2	0.89 (0.14)	0.81 (0.15)	0.80 (0.20)	2.47	0.092
SRL2 Win-stay 6	0.92 (0.17)	0.87 (0.13)	0.77 (0.19)#	5.02	0.009
SRL2 Lose-shift	0.52 (0.23)	0.57 (0.25)	0.60 (0.23)	0.73	0.485
Computational modelling					
EWA <i>phi</i>	0.22 (0.21)	0.10 (0.10) #	0.12 (0.13)	4.18	0.019
EWA <i>rho</i>	0.23 (0.20)	0.23 (0.17)	0.43 (0.29) **	5.55	0.006
EWA <i>beta</i>	2.54 (0.81)	2.10 (0.59)	1.88 (0.70)##	5.80	0.005
RP rew	0.87 (0.02)	0.87 (0.01)	0.86 (0.04)	1.95	0.151
RP pun	0.73 (0.25)	0.90 (0.12)#	0.81 (0.23)	3.40	0.039
RP <i>beta</i>	2.91 (1.38)	1.97 (1.06) #	1.51 (1.24)##	8.50	<0.001

The data are expressed as mean (standard deviation) where applicable. † for SRL2 outcomes, N = 27 for control intact and N = 22 for persistent psychosis impaired groups. *p<0.05, **p<0.01 compared with all groups; *p<0.05, *p<0.01 compared with Controls.

Table S15. Outcome-specific devaluation in a subgroup of control subjects **matched for rating changes towards the devalued stimuli** with persistent psychosis subjects with impaired goal-directed action.

Group	Control	Persistent psychosis	F/χ²	p	
Goal-directed action	intact	impaired			
	(N = 15)	(N = 25)			
Instrumental training					
Total trials to criterion	6.20 (0.77)	7.44 (2.50)	3.46	0.071	
Total correct trials	6.13 (0.52)	6.68 (1.77)	1.35	0.253	
Response rate (s)	1.40 (0.67)	1.80 (0.86)	2.44	0.127	
Correct response rate (s)	1.39 (0.67)	1.44 (0.65)	0.04	0.840	
Devaluation rating change	es				
Valued stimulus	1.20 (1.70)	1.04 (1.62)	0.09	0.768	
Devalued stimulus	-0.93 (1.03)	-0.28 (2.01)	1.36	0.251	
Irrelevant stimulus	0.27 (0.88)	0.08 (1.50)	0.19	0.664	
Motivation to earn credits	0.40 (1.12)	-0.48 (1.36)	4.46	0.041	*
Outcome-specific devalua	tion				
Valued response ratio	0.99 (0.04) aaa	0.45 (0.17) aaa	142.46	<0.001	**
Devalued response ratio	0.01 (0.04)	0.55 (0.17)	142.46	<0.001	**
Valued response rate (/s)	2.88 (0.73) a	1.08 (0.66)	63.47	< 0.001	**
Devalued response rate	0.02 (0.07)	1.27 (0.54)	79.83	<0.001	**
Probe questions					
Average correct responses	1.67 (0.62)	1.12 (0.97)	3.81	0.058	

The data are expressed as mean (standard deviation) where applicable.

^{*}p<0.05, ***p<0.001. ap <0.005, ^{aaa}p <0.001 valued outcome compared with equivalent devalued outcome (paired t-test within group).

Table S16. Serial reversal learning in a sub cohort of control intact subjects **matched for rating changes towards the devalued stimuli** with PP impaired subjects (*see Table S15*).

Group	Control	Persistent psychosis	F/χ²	p	
Goal-directed action	intact (N = 15) †	impaired (N = 24) †			
Trials to criterion					
Initial discrimination	28.87 (69.66)	19.12 (14.79)	0.51	0.479	
First reversal	12.27 (8.31)	31.60 (44.89)	2.17	0.149	
SRL1	16.37 (14.11)	26.51 (22.49)	2.44	0.127	
SRL2	19.27 (10.17)	38.60 (35.54)	3.89	0.057	
Strategy use					
SRL1 Win-stay	0.95 (0.11)	0.83 (0.16)	6.17	0.018	*
SRL1 Lose-shift	0.51 (0.25)	0.59 (0.18)	1.54	0.223	
SRL2 Win-stay	0.91 (0.12)	0.78 (0.19)	3.54	0.069	
SRL2 Win-stay 2	0.88 (0.13)	0.80 (0.20)	0.91	0.349	
SRL2 Win-stay 6	0.95 (0.12)	0.77 (0.19)	7.40	0.010	*
SRL2 Lose-shift	0.52 (0.23)	0.60 (0.23)	0.85	0.363	
Computational modellin	g				
EWA phi	0.24 (0.23)	0.12 (0.13)	4.74	0.036	*
EWA rho	0.24 (0.23)	0.43 (0.29)	4.25	0.046	*
EWA beta	2.55 (0.79)	1.88 (0.70)	7.95	0.008	**
RP rew	0.72 (0.23)	0.81 (0.23)	1.46	0.235	
RP pun	0.87 (0.02)	0.86 (0.04)	1.45	0.236	
RP beta	3.00 (1.45)	1.51 (1.24)	11.90	<0.001	**

The data are expressed as mean (standard deviation) where applicable. † for SRL2 outcomes, N = 14 for control intact and N = 20 for persistent psychosis impaired groups. *p<0.05, **p<0.01, ***p<0.001.

Table S17. Behavioural differences in those with persistent psychosis split for intact or impaired goal-directed action and **matched for IQ**.


Group	Persistent psychosis	Persistent psychosis	F	р	
Goal-directed action	intact (N = 17)	impaired (N = 17)			
General characteristics					
Age (years)	32.2 (9.5)	31.2 (9.9)	0.10	0.753	
Dose (CPZ equivalent)	449.8 (205.6)	575.6 (608.6)	0.65	0.425	
IQ test scores					
TOPF (ss)	103.3 (9.8)	97.3 (14.8)	1.95	0.172	
WASI-II (FISQ-2)	96.6 (11.8)	91.5 (9.6)	1.89	0.179	
Outcome-specific					
Valued response ratio	0.97 (0.05)	0.49 (0.15)	160.27	<0.001	***
Valued response rate (/s)	2.93 (0.76)	1.24 (0.7)	44.62	< 0.001	***
Serial reversal learning					
SRL1 (trials to criterion)	13.88 (8.35)	26.13 (20.46)	5.22	0.029	*
SRL1 Win-stay	0.95 (0.09)	0.83 (0.16)	7.77	0.009	**
SRL1 Lose-shift	0.63 (0.2)	0.63 (0.16)	0.00	0.991	
Computational modelling					
EWA phi	0.16 (0.17)	0.09 (0.06)	0.55	0.463	
EWA rho	0.38 (0.21)	0.48 (0.28)	4.59	0.040	*
EWA beta	2.07 (0.56)	1.96 (0.71)	1.87	0.181	

The data are expressed as mean (standard deviation) where applicable. CPZ, chlorpromazine; TOPF, test of premorbid functioning; ss, standard score; WASI-II, Wechsler Abbreviated Scale of Intelligence – 2^{nd} edition; FSIQ-2, Full-Scale IQ. *p<0.05, **p<0.01, ***p<0.001.



Figure S1. Stimuli used for outcome-specific devaluation tokens. All stimuli were matched for white:black pixel ratio.

A. Training stimuli pairs



B. Serial reversal learning stimuli pairs




Figure S2. Visual stimuli pairs used for serial reversal learning. Two pairs of stimuli were used for the training stage (**A**). Four pairs of stimuli were used for the serial reversal learning test stage (**B**). Pair sets and stimuli assigned as the initial 'correct' stimuli were counterbalanced between groups. All stimuli were matched for white:black pixel ratio.




Figure S3. Correlation between beta values for the experience weighted attraction (EWA) and reinforcement learning (RP) models. The beta values (inverse temperature) estimated by both models correlated highly ($r_{(94)} = 0.89$, p < 0.001), supporting that both models accurately estimate underlying cognitive processes. Standard error is represented by the blue shading.